- Home
- TLS vs LUNG Comparison
TLS vs LUNG Comparison
Compare TLS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLS
- LUNG
- Stock Information
- Founded
- TLS 1969
- LUNG 1995
- Country
- TLS United States
- LUNG United States
- Employees
- TLS N/A
- LUNG N/A
- Industry
- TLS EDP Services
- LUNG Industrial Specialties
- Sector
- TLS Technology
- LUNG Health Care
- Exchange
- TLS Nasdaq
- LUNG Nasdaq
- Market Cap
- TLS 233.1M
- LUNG 256.3M
- IPO Year
- TLS 2020
- LUNG 2020
- Fundamental
- Price
- TLS $3.16
- LUNG $8.96
- Analyst Decision
- TLS Buy
- LUNG Buy
- Analyst Count
- TLS 5
- LUNG 6
- Target Price
- TLS $4.50
- LUNG $11.92
- AVG Volume (30 Days)
- TLS 315.3K
- LUNG 392.8K
- Earning Date
- TLS 03-14-2025
- LUNG 02-19-2025
- Dividend Yield
- TLS N/A
- LUNG N/A
- EPS Growth
- TLS N/A
- LUNG N/A
- EPS
- TLS N/A
- LUNG N/A
- Revenue
- TLS $122,959,000.00
- LUNG $83,789,000.00
- Revenue This Year
- TLS N/A
- LUNG $22.26
- Revenue Next Year
- TLS $38.31
- LUNG $18.72
- P/E Ratio
- TLS N/A
- LUNG N/A
- Revenue Growth
- TLS N/A
- LUNG 22.01
- 52 Week Low
- TLS $1.89
- LUNG $5.46
- 52 Week High
- TLS $5.03
- LUNG $11.73
- Technical
- Relative Strength Index (RSI)
- TLS 43.61
- LUNG 75.17
- Support Level
- TLS $3.45
- LUNG $6.50
- Resistance Level
- TLS $3.71
- LUNG $9.37
- Average True Range (ATR)
- TLS 0.20
- LUNG 0.54
- MACD
- TLS -0.00
- LUNG 0.26
- Stochastic Oscillator
- TLS 30.38
- LUNG 89.21
About TLS Telos Corporation
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.